pathology
revealed
News & Articles
A Novel Pipeline Framework for Digital Assay Development in Pathology and Multi-omics – Part Two
This is Part Two in a series. In Part One, learn how Reveal’s digital assay pipeline addresses common logistical and technical challenges associated with digital image analysis . What are the current capabilities of the
A Novel Pipeline Framework for Digital Assay Development in Pathology and Multi-omics – Part One
Analyzing whole slide pathology images at scale is challenging due to the large size of the data and the complexity of models required to quantify a broad range of tissue types and diseases. Reveal Biosciences
In Situ Hybridization: Ingredients for Success
What is in situ hybridization? In situ hybridization (ISH) is a method which allows the localization of specific DNA or RNA sequences within a section of tissue using a labeled complementary strand. The target gene
The Future of Pharma: Using Artificial Intelligence to Optimize Clinical Trials – Part Two
This is Part Two in a series. In Part One, learn how precision pathology is connected to clinical trials and the important factors in patient selection and enrollment. Patient Stratification A critical challenge in any
The Future of Pharma: Using Artificial Intelligence to Optimize Clinical Trials – Part One
Precision Pathology and Clinical Trials Anatomic pathology, as an objective measure, can provide valuable insights in clinical trials. However, interpretation of pathology results by human eyes can be limited, time consuming, and in some cases
Multiplex Assays for Spatial Biology: An Interview with Dr. Christopher Kerfoot
We sat down with Dr. Christopher Kerfoot, Global Strategic Advisor of Histopathology at CellCarta & Co-founder of Mosaic Laboratories, who provided an in-depth examination of the cutting-edge multiplex technology that is being deployed at CellCarta
CellCarta Launches Advanced AI-Powered Spatial Biology Data for Clinical Trials
LAKE FOREST, CA, March 1st, 2022 – CellCarta, a global provider of precision medicine services, announced today the launch of imageDx PRISM to significantly advance the spatial biology data achievable from Akoya Bioscience’s ® multiplex
Reveal Biosciences Joins the CellCarta Family
CellCarta Strengthens its Histological Biomarker Franchise by Acquiring Artificial Intelligence-Based Quantitative Pathology Leader Reveal Biosciences MONTREAL, Canada, May 11th, 2021 / CNW – CellCarta, a global provider of precision medicine services, announced today the acquisition
Reveal Biosciences Creates A New Artificial Intelligence Approach to Spatial Genomics in Partnership with QuantumCyte
The partnership paves way for the integration of AI-driven spatial genomics with a unique cloud-based platform (SAN DIEGO, Jan. 19, 2021) — Reveal Biosciences, Inc., a leader in AI digital Pathology Intelligence™, announced today its
Reveal Biosciences’ AI-powered imageDx™ platform expedites pathology review of over 3,500 slides for COVID study
The universal demand to bring a COVID vaccine to market has expedited timelines in both preclinical and clinical research. While vaccine development efforts have been accelerated, traditional pathology evaluation struggles to change: Hematoxylin & Eosin-stained
